{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-038577","form_type":"8-K","ticker":"RLMD","cik":"0001553643","company_name":"RELMADA THERAPEUTICS, INC.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.365417+00:00","generated_at":"2026-06-15T04:06:15.963934+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Relmada Therapeutics reports Q1 2023 net loss of $26.3M; provides REL-1017 trial update","bullets":["Net loss of $26.3M ($0.87 per share) vs $39.7M ($1.40) in Q1 2022.","R&D expense fell to $15.9M from $25.0M, driven by completion of RELIANCE I and III studies.","Cash, cash equivalents, and short-term investments of $132.4M as of March 31, 2023.","Enrollment ongoing in Phase 3 Study 302 (REL-1017 for MDD); completion expected H1 2024.","New Phase 3 Study 304 to start mid-2023 with ~300 patients; completion anticipated H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-038577","json":"https://secwatch.observer/filing/0001213900-23-038577.json","markdown":"https://secwatch.observer/filing/0001213900-23-038577.md","text":"https://secwatch.observer/filing/0001213900-23-038577.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023038577/0001213900-23-038577-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023038577/ea178401-8k_relmada.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:06:15.963934+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2985d6e8b66477cc58a019a59c654a808212e674","claim":"RELMADA THERAPEUTICS, INC. reported first quarter ended March 31, 2023 results: net income Net loss for the three months ended March 31, 2023, was $26.3 million, or $0.87 per basic and diluted share, EPS $0.87 per basic and diluted share.","evidence_excerpt":"Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the first quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023038577/0001213900-23-038577-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Net income","value":"Net loss for the three months ended March 31, 2023, was $26.3 million, or $0.87 per basic and diluted share"},{"label":"EPS","value":"$0.87 per basic and diluted share"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}